Peptides DB
Research-centric peptide and protocol reference hub
Study 3 of 4TB-500 Ac-LKKTETQ literaturebiorxiv-preprint · Observational2026

Inherited human TFIIIA deficiency disrupts T cell development

TFIIIA deficiency is identified as a novel genetic cause of severe combined immunodeficiency, highlighting its critical role in T cell development.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the tb-500 ac-lkktetq corpus
0
Preclinical
3
Observational · this one
0
Open-label
1
Randomised
0
Reviews

Summary and findings

This study investigates biallelic deleterious variants in GTF3A, which encodes transcription factor IIIA (TFIIIA), in patients with severe combined immunodeficiency (SCID) or combined immune deficiency (CID). The research identifies ten patients from eight unrelated families across eight countries and describes the mechanisms by which TFIIIA deficiency affects T cell development. No therapeutic claims are made.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

<h4>ABSTRACT</h4> Molecular characterization of human monogenic inborn errors of T cell immunity provides both biological insights and medical progress. We report rare biallelic deleterious variants in GTF3A , encoding transcription factor IIIA (TFIIIA), a zinc-finger protein required for transcription and chaperoning of 5S ribosomal RNA (rRNA). These variants were identified in ten patients from eight unrelated families and eight countries presenting with either T - B + NK + severe combined immunodeficiency (SCID) or combined immune deficiency (CID), characterized by T cell lymphopenia and variable antibody deficiency. The GTF3A variants disrupt TFIIIA function through distinct mechanisms, including defective DNA binding, aberrant nuclear localization, and reduced protein stability compromising TFIIIA-mediated transcription and chaperoning of 5S rRNA. Using artificial thymic organoids derived from TFIIIA-deficient CD34⁺ progenitors, an early developmental arrest at the T cell commitment stage was documented in vitro . Zebrafish deficient for gtf3aa recapitulated the impaired thymocyte development in vivo . Together, these findings establish TFIIIA deficiency as a novel cause of (S)CID, expanding the genetic and mechanistic landscape of inborn errors of T cell immunity and uncovering an essential role for TFIIIA in human adaptive immunity. <h4>One-sentence summary</h4> Biallelic GTF3A variants causing TFIIIA deficiency, which disrupts 5S rRNA transcription, represent a novel monogenic cause of (S)CID, unveiling a crucial role of TFIIIA in T cell development.

Background

The study appears to investigate the role of TFIIIA, a transcription factor, in T cell development. TFIIIA is known to be involved in transcriptional regulation, but its specific role in immune cell development is not well understood. This research could provide insights into genetic factors affecting immune system function.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Without access to the abstract or full text, it is difficult to assess how this study compares to existing literature or its clinical significance. The title suggests a genetic deficiency affecting T cell development, which could have implications for understanding immune disorders.

Key findings

  • Not reported in abstract.

Limitations

  • Abstract not available
  • Preprint status, not peer-reviewed
  • Unknown sample size
  • Unknown study design
  • Unknown dosing information

Elsewhere in the TB-500 Ac-LKKTETQ corpus

BFrom sample to insight: Onsite training and implementing mobile environmental surveillance in sub-Saharan Africabiorxiv-preprint · 2026 · 83 samples sequenced using long-read metagenomic sequencing.HumanAA Controlled Human Malaria Infection model for relapsing <i>Plasmodium vivax</i>biorxiv-preprint · 2026 · 3.6 relapse infections per person-year.HumanCSimultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro.europepmc · 2024 · Not reported in abstract.Animal